Premium
MAL‐PDT for difficult to treat nonmelanoma skin cancer
Author(s) -
Stebbins William G.,
Hanke C. William
Publication year - 2011
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2010.01381.x
Subject(s) - medicine , skin cancer , photodynamic therapy , dermatology , field cancerization , basal cell , basal cell carcinoma , cancer , chemistry , organic chemistry
With an incidence of over 3.5 million nonmelanoma skin cancers (NMSCs) per year in the United States, there is an increasing need for effective, cost‐effective treatments for NMSC. When surgical excision is impractical or not feasible, methyl aminolevulinate photodynamic therapy (MAL‐PDT) has demonstrated consistently high long‐term cure rates ranging from 70–90%, with superior cosmetic outcomes compared with other treatment modalities. With the exception of invasive squamous cell carcinoma, MAL‐PDT has been successful in treating all types of NMSC, especially in patients with multiple comorbidities, field cancerization, and lesions in cosmetically sensitive locations. Herein, a step‐by‐step description of the procedure for MAL‐PDT is provided, followed by a review of outcomes from large clinical trials performed over the past 15 years for each variant of NMSC. After reading this review, clinicians should have a thorough understanding of the benefits and limits of MAL‐PDT, and should be able to add this valuable procedure to their armamentarium of therapies for NMSC.